CDK inhibitors and radiation therapy in breast cancer: Hematologic toxicity and survival implications. A phase I dose-escalation study of a first-in-class HIF1 and HIF2 dual inhibitor R01 in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results